FDA approval of apixaban for stroke prevention in AF: The "tipping point" for novel oral anticoagulants

With three novel drugs—dabigatran, rivaroxaban, and now apixaban—approved for stroke prevention in AF, the tide is changing on oral anticoagulation. It's time to set aside our (very human) tendency to avoid change and acknowledge the evidence for the uptake of these new agents.

See also:

FDA approves apixaban for stroke prevention in nonvalvular AF

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation.  N Engl J Med 2011; 365:981-992. Abstract.

Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism.  N Engl J Med 2012; DOI:10.1056/NEJMoa1207541. Abstract.

Your comments

	FDA approval of apixaban for stroke prevention in AF: The "tipping point" for novel oral anticoagu
	# 1 of 2	February 4, 2013 03:04 (EST)
	Garth Dawley	Dabigitran a trigger for Afib Although I have communicated to every known infprmation and medical source about my experience with dabigitran the medical community blithely soldiers on professing it to be a mirical drug in stroke prevention in Afib affected individuals. It nearly killed me with the frequent and violent recurrences of arythmia and has left me virtually mute with my vocal chords paralized. Author's disclosure (Feb 4, 2013) I have no relevant disclosures to make in connection with this topic.
	# 2 of 2	February 4, 2013 09:45 (EST)
	Melissa Walton-Shirley	Garth I am unaware of a signal of rhythm issue in any study. Furthermore, I"m not aware of vocal chord issues. Please have a frank discussion with your cardiologist regarding your concerns. Author's disclosure (Feb 4, 2013) I have no relevant disclosures to make in connection with this topic.

You must be a member (with full membership) to post a comment.

Already a member?

Enter your login information below:

 Remember me on this computer

Forgot your username and/or password?

        Login        

Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

    Join now for full access